Lazard Asset Management LLC Mirati Therapeutics, Inc. Transaction History

Lazard Asset Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$41.99 - $62.38 $54,335 - $80,719	1,294 New	1,294 $76,000
Q1 2022 May 13, 2022	SELL	$75.82 - $150.97 $26,385 - $52,537	-348 Closed	0 $0
Q4 2021 Feb 09, 2022	SELL	$132.01 - $190.29 $565,926 - $815,773	-4,287 Reduced 92.49%	348 $51,000
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $612,422 - $822,480	4,635 New	4,635 $819,000
Q3 2020 Nov 13, 2020	SELL	$113.26 - $167.27 $2,151 - $3,178	-19 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$72.01 - $120.39 $1,368 - $2,287	19 New	19 $2,000
Q1 2018 May 14, 2018	SELL	$17.2 - $34.95 $350,587 - $712,385	-20,383 Closed	0 $0
Q4 2017 Feb 13, 2018	BUY	$12.65 - $19.0 $257,844 - $387,277	20,383	20,383 $371,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lazard Asset Management LLC with notifications on news.